Project Grant R01AI183508
Award Date 9/15/25
Completion Date 8/31/30
Dollars Obligated $139K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tanzania
Similar Awards
- This Project Grant award, valued at $2,324,448.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose is to optimize an oral BCG (Bacille Calmette-Guerin) vaccination regimen against tuberculosis (TB), a leading cause of infectious death worldwide. The research aims to: 1) Optimize the oral BCG regimen, 2) Compare the efficacy of oral BCG to intravenous and intradermal BCG in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $299,644 to L2 Diagnostics LLC to develop a transmission-blocking vaccine (TBV) candidate that targets novel mosquito metabolic pathways to disrupt the transmission cycle of malaria. The goal is to create a vaccine that can be used alongside existing malaria vaccines to help eradicate the disease in...
- This $190,892 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support a study to optimize tuberculosis (TB) active case finding strategies in Nairobi, Kenya. The key products and services to be delivered include: Employing multiple data sources on human mobility and activity spaces to identify high-yield geographic locations for TB screening within Nairobi. Developing a geospatial model to estimate...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- This $412,581 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to define the roles of specialized mitochondrial DNA polymerases (POLIB and POLID) in the replication and maintenance of the complex kinetoplast DNA network of African trypanosomes. These parasites cause neglected tropical diseases such as human African trypanosomiasis, Chagas disease,...
- This $1,486,800 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the unexpected role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against Herpes Simplex Virus (HSV). The research involves engineering a novel single-cycle HSV vaccine strain, isolating potent...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $666,567 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Statens Serum Institut, a Danish government-owned infectious disease research organization. The grant, awarded in August 2025, aims to determine the role of vaccine-induced Th17 cells in protective immunity against tuberculosis (TB). The research objectives include assessing the contribution of...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will provide up to $176,738 to Boston University Medical Campus over a 5-year period from September 1, 2025 to August 31, 2030. The grant will support research to optimize COVID-19 vaccination strategies in Malawi, a sub-Saharan African country, with a focus on assessing the longevity of antibody responses, the role of innate immunity, and the...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- This $1,450,790 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), is for the "RE-EVALUATING THE DURATION IN CHILDREN OF TB TREATMENT (REDUCE TB): A PHASE 2 DURATION RANDOMIZED TRIAL" project. The project aims to address the significant public health challenge of tuberculosis (TB) in children, with approximately 1.3 million new cases reported globally in...